(Q81354821)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

David M Jackman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Bruce E Johnson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

366

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1385-1396

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

9494

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

cites work

Oat cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Lung cancer in Europe in 2000: epidemiology, prevention, and early detection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Gender and Histologic Type Variations in Smoking-Related Risk of Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Effect of smoking cessation on major histologic types of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Transient elevation of messenger RNA encoding gastrin-releasing peptide, a putative pulmonary growth factor in human fetal lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

The role of c-myc in regulation of translation initiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

The p53 tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

FHIT as tumor suppressor: mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

The FHIT gene 3p14.2 is abnormal in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung Carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Replacement of Fhit in cancer cells suppresses tumorigenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

The IARC TP53 database: new online mutation analysis and recommendations to users

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Increasing use of bronchoscopic needle aspiration to diagnose small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Small cell carcinoma versus other lung malignancies: diagnosis by fine-needle aspiration cytology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Small-cell lung cancer: importance of fiberoptic bronchoscopy in the evaluation of complete remission.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

A prospective study of patients with lung cancer and hyponatremia of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Biosynthesis of vasopressin in vitro and ultrastructure of a bronchogenic carcinoma. Patient with the syndrome of inappropriate secretion of antidiuretic hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Systemic diseases associated with disorders of water homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Superiority of Demeclocycline over Lithium in the Treatment of Chronic Syndrome of Inappropriate Secretion of Antidiuretic Hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

ACTH precursors characterize the ectopic ACTH syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Quantal components of end-plate potentials in the myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Lambert-eaton myasthenic syndrome: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Apheresis treatment in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Positron emission tomography in limited-stage small-cell lung cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Long term results of surgery and chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Radiation therapy for chest recurrences following induction chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Stereotactic radiosurgery for the treatment of brain metastases. Results of a single institution series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Comparison of three treatment options for single brain metastasis from lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Long-term survival in small cell lung cancer: the case for a standard definition. Medical Research Council Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

Long term survival of small cell lung cancer patients after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967569-1

7 January 2021

10.1016/S0140-6736(05)67569-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16226617%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference